|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang B, Tang J, Liao D, et al: Chromobox
homolog 4 is correlated with prognosis and tumor cell growth in
hepatocellular carcinoma. Ann Surg Oncol. 20:S684–S692. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aravalli RN, Steer CJ and Cressman EN:
Molecular mechanisms of hepatocellular carcinoma. Hepatology.
48:2047–2063. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tameda M, Sugimoto K, Shiraki K, et al:
Collagen triple helix repeat containing 1 is overexpressed in
hepatocellular carcinoma and promotes cell proliferation and
motility. Int J Oncol. 45:541–548. 2014.PubMed/NCBI
|
|
6
|
Lim LP, Lau NC, Garrett-Engele P, et al:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Landgraf P, Rusu M, Sheridan R, et al: A
mammalian microRNA expression atlas based on small RNA library
sequencing. Cell. 129:1401–1414. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bai S, Nasser MW, Wang B, et al:
microRNA-122 inhibits tumorigenic properties of hepatocellular
carcinoma cells and sensitizes these cells to sorafenib. J Biol
Chem. 284:32015–32027. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fang JH, Zhou HC, Zeng C, et al:
MicroRNA-29b suppresses tumor angiogenesis, invasion, and
metastasis by regulating matrix metalloproteinase 2 expression.
Hepatology. 54:1729–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou L, Yang ZX, Song WJ, et al:
MicroRNA-21 regulates the migration and invasion of a stem-like
population in hepatocellular carcinoma. Int J Oncol. 43:661–669.
2013.PubMed/NCBI
|
|
12
|
Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP and
Zhuang SM: MicroRNA-195 suppresses tumorigenicity and regulates
G1/S transition of human hepatocellular carcinoma cells.
Hepatology. 50:113–121. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu L, Chen L, Xu Y, Li R and Du X:
microRNA-195 promotes apoptosis and suppresses tumorigenicity of
human colorectal cancer cells. Biochem Biophys Res Commun.
400:236–240. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li D, Zhao Y, Liu C, et al: Analysis of
miR-195 and miR-497 expression, regulation and role in breast
cancer. Clin Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin Y, Wu J, Chen H, et al:
Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated
cell cycle arrest in bladder cancer cells. FEBS Lett. 586:442–447.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang QQ, Xu H, Huang MB, et al:
MicroRNA-195 plays a tumor-suppressor role in human glioblastoma
cells by targeting signaling pathways involved in cellular
proliferation and invasion. Neuro Oncol. 14:278–287. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang R, Zhao N, Li S, et al: MicroRNA-195
suppresses angiogenesis and metastasis of hepatocellular carcinoma
by inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology.
58:642–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Luis NM, Morey L, Mejetta S, et al:
Regulation of human epidermal stem cell proliferation and
senescence requires polycomb- dependent and -independent functions
of Cbx4. Cell Stem Cell. 9:233–246. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bracken AP and Helin K: Polycomb group
proteins: navigators of lineage pathways led astray in cancer. Nat
Rev Cancer. 9:773–784. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gieni RS and Hendzel MJ: Polycomb group
protein gene silencing, noncoding RNA, stem cells, and cancer.
Biochem Cell Biol. 87:711–746. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gil J, Bernard D, Martinez D and Beach D:
Polycomb CBX7 has a unifying role in cellular lifespan. Nat Cell
Biol. 6:67–72. 2004. View Article : Google Scholar
|
|
22
|
Bernard D, Martinez-Leal JF, Rizzo S, et
al: CBX7 controls the growth of normal and tumor-derived prostate
cells by repressing the Ink4a/Arf locus. Oncogene. 24:5543–5551.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yap KL, Li S, Munoz-Cabello AM, et al:
Molecular interplay of the noncoding RNA ANRIL and methylated
histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing
of INK4a. Mol Cell. 38:662–674. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kagey MH, Melhuish TA and Wotton D: The
polycomb protein Pc2 is a SUMO E3. Cell. 113:127–137. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ismail IH, Gagne JP, Caron MC, et al:
CBX4-mediated SUMO modification regulates BMI1 recruitment at sites
of DNA damage. Nucleic Acids Res. 40:5497–5510. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li J, Xu Y, Long XD, et al: Cbx4 governs
HIF-1α to potentiate angiogenesis of hepatocellular carcinoma by
its SUMO E3 ligase activity. Cancer Cell. 25:118–131. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hong J, Hu K, Yuan Y, et al: CHK1 targets
spleen tyrosine kinase (L) for proteolysis in hepatocellular
carcinoma. J Clin Invest. 122:2165–2175. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang ZY: Hepatocellular carcinoma - cause,
treatment and metastasis. World J Gastroenterol. 7:445–454.
2001.
|
|
30
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Su H, Yang JR, Xu T, et al: MicroRNA-101,
downregulated in hepatocellular carcinoma, promotes apoptosis and
suppresses tumorigenicity. Cancer Res. 69:1135–1142. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou X, Zhang CZ, Lu SX, et al: miR-625
suppresses tumour migration and invasion by targeting IGF2BP1 in
hepatocellular carcinoma. Oncogene. Mar 17–2014.(Epub ahead of
print). View Article : Google Scholar
|
|
33
|
Shih TC, Tien YJ, Wen CJ, et al:
MicroRNA-214 downregulation contributes to tumor angiogenesis by
inducing secretion of the hepatoma-derived growth factor in human
hepatoma. J Hepatol. 57:584–591. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang X, Yin J, Yu J, et al: miRNA-195
sensitizes human hepatocellular carcinoma cells to 5-FU by
targeting BCL-w. Oncol Rep. 27:250–257. 2012.
|
|
35
|
Bhattacharya A, Schmitz U, Wolkenhauer O,
Schönherr M, Raatz Y and Kunz M: Regulation of cell cycle
checkpoint kinase WEE1 by miR-195 in malignant melanoma. Oncogene.
32:3175–3183. 2013. View Article : Google Scholar
|
